RBOT
Vicarious Surgical Inc.2.4300
-0.0400-1.62%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
16.48MP/E (TTM)
-Basic EPS (TTM)
-9.03Dividend Yield
0%Recent Filings
8-K
Delisting, cuts losses 20%
Vicarious Surgical reported FY 2025 net loss of $50.2M, down from $63.2M in 2024, with operating expenses cut 25% to $50.0M and cash at $9.8M. Cash burn hit $45.1M, beating guidance. Stock delisted from NYSE March 3, 2026, now trades OTCID as RBOT; no appeal filed. Guides $19M cash burn for 2026. Liquidity shrinks fast.
10-K
FY2025 results
Vicarious Surgical posted FY2025 net loss of $50.2M, improved from $63.2M in 2024, on 25% operating expense cut to $50.0M amid 23% headcount drop to 98 average employees; R&D fell 16% to $33.6M, sales/marketing halved to $2.2M, G&A down 31% to $15.2M. Cash burned $45.1M in operations, ending with $9.8M liquidity but substantial going-concern doubt, runway now to Q2 2026 post March 2026 cuts. No revenue yet; Vicarious System awaits FDA De Novo for ventral hernia amid delisting to OTCID. Cash too low.
8-K
Execs cut salaries voluntarily
Vicarious Surgical amended employment agreements for President Adam Sachs and CTO Sammy Khalifa on March 4, 2026, effective March 9, slashing their base salaries to $270,810 and $318,600 annually. Bonuses and severance stick to prior higher rates. Execs voluntarily waived Good Reason claims. Cash conservation amid NYSE delisting.
8-K
NYSE delists Vicarious Surgical
Vicarious Surgical's stock trading suspended by NYSE on March 3, 2026, after average global market cap fell below $15M over 30 days, triggering delisting proceedings. Company eyes appeal but secured OTCID quotation starting March 4 under RBOT. Less liquid OTC trading risks lower prices, fewer investors, and stalled equity raises.
8-K
Exec severance deals updated
Vicarious Surgical amended CEO Stephen From's employment agreement on February 2, 2026, boosting standard severance to 12 months base salary plus pro-rata bonus and COBRA, doubling to 24 months post-change-in-control with full equity vesting. CFO Sarah Romano signed a new severance deal on February 1, offering 6 months standard pay but 12 months enhanced around change-in-control. Executives gain retention security. Severance requires release and covenants.
IPO
Employees
Sector
Industry
BSX
Boston Scientific Corporation
92.95+0.76
ISRG
Intuitive Surgical, Inc.
554.58-4.94
LNSR
LENSAR, Inc.
12.06+0.54
MBOT
Microbot Medical Inc.
2.22+0.01
MDT
Medtronic plc.
97.72-0.85
MGRM
Monogram Technologies Inc.
6.00+0.00
PRCT
PROCEPT BioRobotics Corporation
35.66-0.44
SERV
Serve Robotics Inc.
10.57-0.40
SSII
SS Innovations International In
5.50+0.41
VTAK
Catheter Precision, Inc.
2.19-0.04